Literature DB >> 10739303

Melatonin receptors in human uveal melanocytes and melanoma cells.

J E Roberts1, A F Wiechmann, D N Hu.   

Abstract

Previous work has demonstrated that melatonin inhibits growth of cultured human uveal melanoma cells. The goal of this study was to determine the expression of mRNA encoding the melatonin receptor subtypes and the effect of specific melatonin receptor agonists on cell growth of uveal melanoma cells and melanocytes. RNA expression of the human melatonin Mel1a and Mel1b receptor subtypes was determined by reverse transcription-polymerase chain reaction (RT-PCR) amplification of RNA isolated from two melanoma cell lines and from one cell line of normal melanocytes. PCR-amplified cDNA encoding the Mel1b melatonin receptor subtype, but not the Mel1a subtype, was detected in reverse-transcribed RNA obtained from both normal uveal melanocytes and melanoma cell lines. Uveal melanoma cells and melanocytes were cultured for 24 hr, then melatonin or one of its membrane receptor agonists, 6-chloromelatonin (Mel1a-1b) or S-20098 (Mel1b) or its putative nuclear agonist, CGP-52608 (Mel2), was added to the medium. After 5 days, the cells were detached, counted, and compared to untreated controls. Melatonin and its membrane receptor agonists (Mel1a-1b and Mel1b), but not its putative nuclear receptor agonist (Mel2), inhibited the growth of uveal melanoma cells, but not normal melanocytes, at very low concentrations. In uveal melanoma cells, the expression of RNA encoding the Mel1b receptor suggests that the growth inhibiting effect of melatonin on uveal melanoma cells is related to activation of the melatonin Mel1b membrane receptor. Furthermore, the expression of RNA encoding melatonin receptors in normal uveal melanocytes suggests that melatonin may play a role in the function of these cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739303     DOI: 10.1034/j.1600-079x.2001.280306.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  8 in total

Review 1.  Melatonin: A Cutaneous Perspective on its Production, Metabolism, and Functions.

Authors:  Andrzej T Slominski; Ruediger Hardeland; Michal A Zmijewski; Radomir M Slominski; Russel J Reiter; Ralf Paus
Journal:  J Invest Dermatol       Date:  2018-02-07       Impact factor: 8.551

2.  Residential and occupational exposure to 50 Hz magnetic fields and malignant melanoma: a population based study.

Authors:  T Tynes; L Klaeboe; T Haldorsen
Journal:  Occup Environ Med       Date:  2003-05       Impact factor: 4.402

3.  A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation.

Authors:  Michele Fornaro; Davide Prestia; Salvatore Colicchio; Giulio Perugi
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

4.  Melatonin receptor agonist-induced reduction of SNP-released nitric oxide and cGMP production in isolated human non-pigmented ciliary epithelial cells.

Authors:  Juanita Dortch-Carnes; Gianluca Tosini
Journal:  Exp Eye Res       Date:  2012-11-29       Impact factor: 3.467

Review 5.  Influence of Circadian Rhythm in the Eye: Significance of Melatonin in Glaucoma.

Authors:  Alejandro Martínez-Águila; Alba Martín-Gil; Carlos Carpena-Torres; Cristina Pastrana; Gonzalo Carracedo
Journal:  Biomolecules       Date:  2021-02-24

Review 6.  The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature.

Authors:  Anna Hagström; Ruba Kal Omar; Pete A Williams; Gustav Stålhammar
Journal:  BMC Cancer       Date:  2022-04-13       Impact factor: 4.430

Review 7.  Melatonin's neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders.

Authors:  Lindsay M Melhuish Beaupre; Gregory M Brown; Vanessa F Gonçalves; James L Kennedy
Journal:  Transl Psychiatry       Date:  2021-06-02       Impact factor: 6.222

8.  Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance.

Authors:  Matteo Martino; Giulio Rocchi; Andrea Escelsior; Michele Fornaro
Journal:  Curr Neuropharmacol       Date:  2012-06       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.